Navigation Links
Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
Date:10/26/2010

ass of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. Resolvyx currently has two programs in clinical development. RX-10045 is a topical eye drop that has completed a Phase II trial in chronic dry eye. RX-10001 is formulated for oral delivery and has completed Phase I. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of over 80 patents and applications. The company's headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.resolvyx.com.

About Resolvins

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis.

ENQUIRIES U.K. Media Relations Susan Quigley, tel: +44(0)207-269-7169; Susan.Quigley@fd.com U.S. Media Relations Robert Stanislaro, tel: +1(212)850-5657; Robert.stanislaro@fd.com Irma Gomez-Dib, tel: +1(212)850-5761; Irma.Gomez-Dib@fd.com
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
2. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
3. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
4. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
5. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
6. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
7. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
8. Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
9. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
10. Prime Therapeutics Receives 2011 TIPPS Certification
11. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Trovagene, Inc. (NASDAQ:   TROV), a developer ... two clinical studies will be presented at the 29th ... test for the detection of high risk strains of ... take place in Seattle from ... a new U.S. patent was issued earlier this year ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive Devices ... medical device company, announced today that Mitsubishi Corporation has ... robotic visualization system in Japan . ... in Japan in the second ... the exclusive distributor for Karl Storz GMBH & Co. ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced ... donation drive that benefits the animal shelter and rescue communities. ... with the Humane Society of the United States’ Animal Shelter ... , As part of their participation, Park Cities Pet Sitter ... the Presents 4 Pets drive from their client base, as ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number ... fastest growing companies. The Inc. 500 ranks Connexion Point 12th, ... Point is the #1 fastest growing company in Utah. , ... and its clients include four of the top 10 health ... and has offices and contact centers in Salt Lake City, ...
(Date:8/20/2014)... cancer - using Botox. A study presented in the ... shows that cancer growth could be suppressed by eliminating ... cancer stem cells. The approach thus treated the cancer. ... and efficient. The researchers have thus far tested the ... humans. , The nervous system is crucial in regulating ...
(Date:8/20/2014)... most common cause of endophthalmitis, a potentially blinding condition ... eye injections, are the well-known staphylococci ("staph") ... a study published in the August issue of ... years of cases at New York Eye and Ear ... study found that gram-positive bacteria, which include staph and ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Treating gastric cancer -- with Botox 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... Pills Can Make Headaches Worse, YONKERS, N.Y., ... from frequent headaches to talk to their doctors,before ... prescription,and over-the-counter pain medications can make headaches worse, ... who reports in,CR,s October issue on how some ...
... Resources and Helpline Now,Available, HARRISBURG, Pa., Sept. 2 ... Indoor Air Act fast approaching, the,Department of Health is ... the law that will ban smoking in most public ... Guidance and a downloadable toolkit for public places ...
... new presidential,administration on the way, health care reform ... on what may come, attendees of the 2008,Republican ... than,Halleland Health Consulting, which is making itself available ... group and its law firm parent -- Minneapolis-based,Halleland ...
... Inc.,(NYSE: CSA ) announces the signing of ... office building and outpatient treatment center in,Pensacola, Florida., ... first synergy project since the,closing of the merger ... Spencer Company). The project will include design/build,(architectural, engineering ...
... Californians took benefit of nation,s 1st such law, passed in ... with chronically ill kids have made use of California,s pioneering ... even aware it exists, according to researchers at the Rand ... family leave law. It is funded by employees through an ...
... Pollution, HARRISBURG, Pa., Sept. 2 The ... partnerships have,forecast an air quality action day for ... air quality forecast predicts Wednesday will be code ... Washington and,Westmoreland counties., The U.S. Environmental Protection ...
Cached Medicine News:Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 2Health News:Consumer Reports Urges Chronic Headache Sufferers to Examine Their Use of Pain Relief Drugs 3Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:INTERVIEW AVAILABILITY: Halleland Health Consulting Makes Health Policy Expertise Available During RNC Week 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 3Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:Air Quality Action Day Forecast Wednesday for Pittsburgh Region 2